Harmony Biosciences Holdings (HRMY) Cash from Financing Activities (2019 - 2026)

Harmony Biosciences Holdings has reported Cash from Financing Activities for 8 years, with the latest figure at -$7.2 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 1950.57% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.9 million (down 106.31% YoY) and the FY2025 annual result came in at -$9.0 million, up 17.71% from the prior year.
• Cash from Financing Activities slipped to -$7.2 million in Q1 2026 per HRMY's latest filing, from -$3.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $3.4 million in Q1 2023 and troughed at -$55.1 million in Q3 2023.
• A 5-year average of -$7.4 million and a median of -$2.7 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 11425.0% in 2022, then sank 2787.76% in 2023.
• Over 5 years, Cash from Financing Activities stood at $2.7 million in 2022, then tumbled by 2113.66% to -$53.5 million in 2023, then surged by 94.88% to -$2.7 million in 2024, then fell by 10.0% to -$3.0 million in 2025, then sank by 139.4% to -$7.2 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$7.2 million, -$3.0 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.